A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme
Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
To evaluate CAN008 safety, tolerability, and pharmacokinetics (PK) of CAN008 when
administered concurrent Plus Concomitant Temozolomide During and After Radiation Therapy in
Patients with Newly Diagnosed Glioblastoma Multiforme.